1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > China Human Vaccine Industry Report, 2015-2018

China Human Vaccine Industry Report, 2015-2018

  • March 2015
  • -
  • Research In China
  • -
  • 138 pages

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to suspected deaths stemming from vaccination and some companies’ (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) production halts of some products because of their failure to pass new GMP certification, China’s human vaccine lot release volume in 2014 declined by 2.4% year on year to 791 million doses.

Affected by China’s less-developed economy, existing national vaccine prevention policies and people’s awareness of epidemic prevention, free EPI vaccines prevail in China with a share of about 80% in the total lot release volume. Chinese free human vaccine market is still dominated by Beijing Tiantan Biological Products, Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises, but their market shares are falling. In 2014, the EPI vaccine lot release volume of Chinese state-owned enterprises accounted for 72%, down 6.5 percentage points compared with the previous year.

However, as China gradually relaxes control over the vaccine market, private companies and foreign players are emerging in market segments of extra EPI vaccine, with their proportions increasing constantly, accounting for 80% in terms of lot release volume. Moreover, private and foreign brands hold a dominant position in the markets of Haemophilus influenza B (Hib), human rabies vaccine, varicella vaccine, and influenza vaccine, together making up 91.9%, 83.6%, 86.5%, and 69.5% in terms of lot release volume in 2014.

Being bullish about China’s demand for human vaccines and exports, many vaccine producers scale up efforts in vaccine R&D or expand capacity, such as Walvax Biotechnology. By early 2015, GMP on-site certification had been carried out for the company’s Diphtheria-tetanus-acellular pertussis combined vaccine adsorbed; HPV bivalent (types 16 and 18) vaccine and DTaP/Hib had made their way into clinical trials; the company is applying registration for meningococcal polysaccharide vaccine (Group A/C/Y/W 135) and other vaccines in Nigeria, Chile, Peru, Thailand, and India.

China Human Vaccine Industry Report, 2015-2018 highlights the following:

Operating environment, overall situation, sales channel, etc. of China human vaccine industry;
Supply & demand, competitive landscape, import & export, and development forecast of the Chinese human vaccine market;
Supply & demand, competitive landscape, and market prices of 10 product segments (including hepatitis B vaccine, influenza vaccine, rabies vaccine, and pneumococcal vaccine) in China;
Operation, vaccine business, and development prospects of 16 Chinese human vaccine companies.

Table Of Contents

China Human Vaccine Industry Report, 2015-2018
1 Overview of Vaccine Industry
1.1 Definition and Classification
1.2 Industry Chain

2 Overview of China Human Vaccine Industry and Market
2.1 Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policy Environment
2.3 Status Quo
2.4 Supply and Demand
2.5 Competitive Landscape
2.6 Developments
2.7 Sales Channel

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Supply and Demand
3.1.2 Competitive Landscape
3.1.3 Market Price
3.2 Meningococcal Vaccine
3.2.1 Supply and Demand
3.2.2 Competitive Landscape
3.2.3 Market Price
3.2.4 Market Forecast
3.3 Hepatitis A Vaccine
3.3.1 Supply and Demand
3.3.2 Competitive Landscape
3.3.3 Market Price
3.3.4 Market Forecast
3.4 Influenza Vaccine
3.4.1 Supply and Demand
3.4.2 Competitive Landscape
3.4.3 Market Price
3.5 Hib Vaccine
3.5.1 Supply and Demand
3.5.2 Competitive Landscape
3.5.3 Market Price
3.5.4 Market Forecast
3.6 Human Rabies Vaccine
3.6.1 Supply and Demand
3.6.2 Competitive Landscape
3.6.3 Market Price
3.6.4 Market Forecast
3.7 Varicella Vaccine
3.7.1 Supply and Demand
3.7.2 Competitive Landscape
3.7.3 Market Price
3.8 Pneumococca Vaccine
3.8.1 Supply and Demand
3.8.2 Competitive Landscape
3.8.3 Market Price
3.9 DTP Vaccine
3.9.1 Supply and Demand
3.9.2 Competitive Landscape
3.9.3 Market Development and Forecast
3.10 Poliomyelitis Vaccine
3.10.1 Supply and Demand
3.10.2 Competitive Landscape

4 China's Import and Export of Vaccines
4.1 Export
4.1.1 Export Volume and Value
4.1.2 Export Destinations
4.2 Import
4.2.1 Import Volume and Value
4.2.2 Sources of Imported Vaccines

5 Major Chinese Vaccine Producers
5.1 China National Biotec Group Co., Ltd.
5.1.1 Beijing Tiantan Biological Products Co., Ltd.
5.1.2 Chengdu Institute of Biological Products Co., Ltd.
5.1.3 Shanghai Institute of Biological Products Co., Ltd.
5.1.4 Wuhan Institute of Biological Products Co., Ltd.
5.1.5 Lanzhou Institute of Biological Products Co., Ltd.
5.1.6 Changchun Institute of Biological Products Co., Ltd.
5.2 Hualan Biological Engineering Inc.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 Customers and Suppliers
5.2.6 RandD and Investment
5.2.7 Vaccine Business
5.2.8 Development Prospect and Forecast
5.3 Chongqing Zhifei Biological Products Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Major Customers
5.3.6 RandD and Investment
5.3.7 Development Prospect and Forecast
5.4 Walvax Biotechnology Co., Ltd.
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Customers and Suppliers
5.4.6 RandD and Investment
5.4.7 Development Prospect and Forecast
5.5 Sinovac Biotech Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 RandD and Investment
5.6 Liaoning Chengda Co., Ltd.
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Major Customers
5.6.6 Liaoning Chengda Biotechnology Co., Ltd
5.6.7 Development Prospect and Forecast
5.7 Changchun BCHT Biotechnology Co. Ltd.
5.7.1 Profile
5.7.2 Operation
5.8 Changchun Changsheng Life Sciences Limited
5.8.1 Profile
5.8.2 Operation
5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.10 Shenzhen Kangtai Biological Products Co. Ltd.
5.10.1 Profile
5.10.2 Operation
5.11 Dalian Hissen Bio-pharm Co., Ltd.
5.11.1 Profile
5.11.2 Operation
5.12 NCPC GeneTech Biotechnology Development Co., Ltd.
5.12.1 Profile
5.12.2 Operation
5.13 Dalian Aleph Biomedical Co., Ltd.
5.13.1 Profile
5.13.2 Operation
5.14 Beijing Minhai Biotechnology Co., Ltd.
5.14.1 Profile
5.14.2 Operation
5.15 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
5.15.1 Profile
5.15.2 Operation
5.16 Jiangsu Simcere Vaxtec Bio-pharmaceutical Co., Ltd.

Companies Mentioned

China National Biotec Group Co., Ltd.
Beijing Tiantan Biological Products Co., Ltd.
Chengdu Institute of Biological Products Co., Ltd.
Shanghai Institute of Biological Products Co., Ltd.
Wuhan Institute of Biological Products Co., Ltd.
Lanzhou Institute of Biological Products Co., Ltd.
Changchun Institute of Biological Products Co., Ltd.
Hualan Biological Engineering Inc.
Chongqing Zhifei Biological Products Co., Ltd.
Walvax Biotechnology Co., Ltd.
Sinovac Biotech Ltd.
Liaoning Chengda Co., Ltd.
Liaoning Chengda Biotechnology Co., Ltd
Changchun BCHT Biotechnology Co. Ltd.
Changchun Changsheng Life Sciences Limited
Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
Shenzhen Kangtai Biological Products Co. Ltd.
Dalian Hissen Bio-pharm Co., Ltd.
NCPC GeneTech Biotechnology Development Co., Ltd.
Dalian Aleph Biomedical Co., Ltd.
Beijing Minhai Biotechnology Co., Ltd.
Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
Jiangsu Simcere Vaxtec Bio-pharmaceutical Co., Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024

OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024

  • $ 9 495
  • Industry report
  • January 2016
  • by Global Data

OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024 Summary Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic ...

Global Therapeutic Vaccines Market Growth, Trends & Forecast 2015 - 2020

Global Therapeutic Vaccines Market Growth, Trends & Forecast 2015 - 2020

  • $ 4 250
  • Industry report
  • January 2016
  • by Mordor Intelligence LLP

The Global market for Therapeutic vaccines is expected to reach US$4.82 billion by the end of 2020 growing at a CAGR of around 33.6% from 2015 to 2020. Several new approaches are being developed in orde ...

Global Veterinary Vaccines Market Segmented by Animal diseases , by Technology, by Animal Type & by Geography - Trends and Forecast 2014-2019

Global Veterinary Vaccines Market Segmented by Animal diseases , by Technology, by Animal Type & by Geography - Trends and Forecast 2014-2019

  • $ 4 250
  • Industry report
  • January 2016
  • by Mordor Intelligence LLP

The Global market for Veterinary Vaccines is currently estimated to be valued at $12.35 billion for the year 2015 and is poised to reach $21.19 billion by the end of 2020. The CAGR during this period of ...

Vaccines Markets In China

March 2016 $ 4 000

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.